Bulletin
Investor Alert

New York Markets After Hours

ZIOPHARM Oncology Inc.

NAS: ZIOP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 13, 2020, 4:05 p.m.

/zigman2/quotes/200291745/composite

$

3.02

Change

-0.0050 -0.17%

Volume

Volume 2,000

Quotes are delayed by 20 min

/zigman2/quotes/200291745/composite

Today's close

$ 3.04

$ 3.03

Change

-0.02 -0.49%

Day low

Day high

$2.90

$3.16

Open

52 week low

52 week high

$1.80

$5.70

Open

Annual Financials for ZIOPHARM Oncology Inc.

Fiscal year is January-December. All values USD millions. 20152016201720182019 5-year trend
Sales/Revenue 4.33M6.86M6.39M146,000-
Cost of Goods Sold (COGS) incl. D&A ----629,000
COGS excluding D&A -----
Depreciation & Amortization Expense 357,000290,000369,000573,000629,000
Depreciation 357,000290,000369,000573,000629,000
Amortization of Intangibles -----
Gross Income ----(629,000)
20152016201720182019 5-year trend
SG&A Expense 114.08M171.88M59.51M53.48M57.23M
Research & Development 96.79M157.79M45.08M34.13M38.33M
Other SG&A 17.29M14.09M14.43M19.35M18.9M
Other Operating Expense -----
Unusual Expense 10M124,0001.3M(158,000)60.75M
EBIT after Unusual Expense (120.1M)(165.43M)(54.79M)(53.75M)(118.61M)
Non Operating Income/Expense 12,000134,000465,000631,000813,000
Non-Operating Interest Income -----
Equity in Affiliates (Pretax) -----
Interest Expense -----
Gross Interest Expense -----
Interest Capitalized -----
Pretax Income (120.09M)(165.3M)(54.32M)(53.12M)(117.8M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (120.09M)(165.3M)(54.32M)(53.12M)(117.8M)
Minority Interest Expense -----
Net Income (120.09M)(165.3M)(54.32M)(53.12M)(117.8M)
Extraordinaries & Discontinued Operations ---207.36M-
Extra Items & Gain/Loss Sale Of Assets ---207.36M-
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (120.09M)(165.3M)(54.32M)154.24M(117.8M)
Preferred Dividends -7.12M18.94M17M-
Net Income Available to Common (120.09M)(172.42M)(73.26M)(70.12M)(117.8M)
EPS (Basic) (0.96)(1.32)(0.53)(0.49)(0.70)
Basic Shares Outstanding 125.42M130.39M136.94M143.51M167.95M
EPS (Diluted) (0.96)(1.32)(0.53)(0.49)(0.70)
Diluted Shares Outstanding 125.42M130.39M136.94M143.51M167.95M
EBITDA (109.74M)(165.02M)(53.12M)(53.33M)(57.23M)
Link to MarketWatch's Slice.